Contents
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders. The company's lead product candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of attention deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas with an additional location in Morristown, New Jersey.
Timeline
No Timeline data yet.
Funding Rounds
Open in Query Tool
Products
Open in Query Tool
Acquisitions
Open in Query Tool
SBIR/STTR Awards
Open in Query Tool
Patents
Open in Query Tool
Further Resources
Title
Author
Link
Type
Date
No Further Resources data yet.
References
Company attributes
Location
CEO
Pitchbook URL
Legal Name
Cingulate Inc.
Number of Employees (Ranges)
11 – 50
Full Address
1901 W 47th Place Kansas City, KS 66205, USA-1
6 South Street, Suite 203 Morristown, New Jersey 07960-1
Founded Date
2012
Email Address
clinicaltrials@cingulate.com-1
rschultz@cingulate.com-1
ir@cingulate.com-1
info@cingulate.com-1
Phone Number
+19139422300
Stock Symbol
CING-1
Exchange
-1
Country
Other attributes
Company Operating Status
Active
Ticker Symbol
CING
